The Chain: Protein Engineering podcast

#Science #Biology #Cambridge Healthtech Institute #Proteins #Protein Engineering #Scientists #RD In #Antibodies #Bispecific Antibodies #Solid Tumors

1:16:55

On her son’s prom night, Mel Robbins fussed over details that didn’t matter. Her daughter grabbed her arm and said, “Let them. Let them run in the rain. Let them eat where they want. Let them.” Those two simple words hit Mel like a ton of bricks and completely changed how she thinks about control. In this episode, Mel shares some of the pivotal moments that shaped her career, her innovative strategies for overcoming adversity, and how the Let Them Theory can help you navigate business challenges, strengthen relationships, and unlock your true power. In this episode, Hala and Mel will discuss: (00:00) Introduction (02:57) The Power of Action (04:22) Mel's Unforgettable TED Talk Debut (07:00) The 5 Second Rule (07:52) Building Unshakable Confidence (12:04) Turning Adversity into Strength (22:00) The Power of Showing Up for Others (30:40) Why Details Matter in Business (42:32) Understanding the Let Them Theory (51:14) The Let Them Theory in Business Mel Robbins is a motivational speaker, the host of The Mel Robbins Podcast, and a bestselling author of several influential books, including her latest, The Let Them Theory. Known for her groundbreaking 5 Second Rule, she has helped millions of people take action and transform their lives. With 30 million views, her TEDx talk made her a recognized voice in behavior change. Mel is also the CEO of 143 Studios, a female-driven media company creating award-winning content for top brands like LinkedIn and Audible. She is a Forbes 50 Over 50 Honoree and one of USA Today’s Top 5 Mindset Coaches. Resources Mentioned: Mel’s Books: The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About : https://amzn.to/4h6quLh The 5 Second Rule: Transform your Life, Work, and Confidence with Everyday Courage : https://amzn.to/3WdAgTX Sponsored By: OpenPhone - Get 20% off 6 months at https://www.openphone.com/PROFITING Shopify - Sign up for a one-dollar-per-month trial period at https://www.youngandprofiting.co/shopify Airbnb - Your home might be worth more than you think. Find out how much at https://www.airbnb.com/host Rocket Money - Cancel your unwanted subscriptions and reach your financial goals faster with Rocket Money. Go to https://www.rocketmoney.com/profiting Indeed - Get a $75 job credit at indeed.com/profiting Active Deals - youngandprofiting.com/deals Key YAP Links Reviews - ratethispodcast.com/yap Youtube - youtube.com/c/YoungandProfiting LinkedIn - linkedin.com/in/htaha/ Instagram - instagram.com/yapwithhala/ Social + Podcast Services : yapmedia.com Transcripts - youngandprofiting.com/episodes-new All Show Keywords: Entrepreneurship, entrepreneurship podcast, Business, Business podcast, Self Improvement, Self-Improvement, Personal development, Starting a business, Strategy, Investing, Sales, Selling, Psychology, Productivity, Entrepreneurs, AI, Artificial Intelligence, Technology, Marketing, Negotiation, Money, Finance, Side hustle, Startup, mental health, Career, Leadership, Mindset, Health, Growth mindset. Career, Success, Entrepreneurship, Productivity, Careers, Startup, Entrepreneurs, Business Ideas, Growth Hacks, Career Development, Money Management, Opportunities, Professionals, Workplace, Career podcast, Entrepreneurship podcast…

The Chain: Protein Engineering Podcast

Distribuie

Pagina seriei•Feed

The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up-to-date on the newest advancements and to hear the stories that are impacting the world of biologics.

73 episoade

The Chain: Protein Engineering Podcast

updated acum 24 zile

Distribuie

Pagina seriei•Feed

73 episoade

#Science #Biology #Cambridge Healthtech Institute #Proteins #Protein Engineering #Scientists #RD In #Antibodies #Bispecific Antibodies #Solid Tumors

Toate episoadele

1
Episode: 70 - Views on Machine Learning and AI in the Antibody and Protein Engineering Space 49:36

acum 24 zile49:36

49:36

March 11, 2025 | In this episode of The Chain, host Andrew Buchanan, principal scientist at AstraZeneca, and Andreas Plückthun, professor and head of biochemistry at the University of Zurich, discuss AI/ML technologies in the antibody and protein engineering space. Plückthun shares his perspectives on what technologies show promise and success, why the definition of epitope is important when developing a drug, and what aspects he expects to improve in the ML field in the future.…

1
Episode: 69 - Conversation with Sir Greg Winter on the 50th Anniversary of the Milstein and Köhler Paper 50:36

acum 6 weeks50:36

50:36

February 21, 2025 | This episode marks the 50th anniversary of one of the most influential papers in biomedical science—the 1975 Milstein and Köhler paper on hybridoma technology, which paved the way for monoclonal antibodies. Ralph Minter, Biotech CSO/CTO, discusses this important milestone with a true pioneer in the field, Sir Greg Winter, Nobel Laureate and one of the key figures in the development of therapeutic antibodies.…

1
Episode: 68 - Changing the Game of Protein-Protein Interactions With Randolph Lopez 46:00

acum 17 weeks46:00

46:00

In this episode of The Chain, host Andrew Bradbury, CSO of Specifica, an IQVIA business, speaks with Randolph Lopez, CTO and co-founder of A-Alpha Bio, about how A-Alpha Bio is changing the game of protein-protein interactions with their platform AlphaSeq. Lopez delves into the origins, the process, the successes, and the possibilities of the company’s platform and how it can help with epitope mapping, affinity predictions, and off-target binding. With the data the platform generates, Lopez also discusses how this affects the potential of AI and ML. LINKS: Bionavigen A-Alpha Bio Specifica…

1
Episode: 67 - Anthony Tolcher Discusses Oncology, Dual-Payload Technology, and the ADC Field 42:34

acum 21 weeks42:34

42:34

November 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload technologies, the potency of new payloads, and bispecific targeting. Tolcher also shares what inspired him to pursue oncology, how he came across ADCs, and where he sees ADCs heading in the future. LINKS: Bionavigen NEXT Oncology…

1
Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond 39:43

acum 24 weeks39:43

39:43

October 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more successful now compared to in the past, and where he sees ADCs going forward. He also discusses his thoughts on the half-life of diffusible payloads, the toxicity of the bystander effect, and more. LINKS: Bionavigen ImmunoGen…

1
Episode 65- Tariq Ghayur on the Renaissance of Bispecifics and ADCs, AI, and More 31:55

acum 30 weeks31:55

31:55

September 10, 2024 | In this episode of The Chain, host Nimish Gera speaks with Tariq Ghayur, founder of FairJourney Biologics (and a fellow host of the podcast), about the current renaissance of bispecifics and ADCs, the impact of AI in pharmaceuticals, and what to watch out for in the biopharma space in the next few years. Ghayur also shares his journey from BASF Pharma to AbbVie, what it was like when the industry shifted its focus from small molecules to biologics, and the major differences between doing a postdoc in academia versus in the industry.…

1
Episode: 64 - Peyton Greenside on AI’s Role in Antibody Engineering, Optimization, and More 32:31

acum 34 weeks32:31

32:31

In this episode of The Chain, host Nimish Gera, Ph.D., vice president of biologics at Mythic Therapeutics, speaks with Peyton Greenside, CSO and co-founder of BigHat Biosciences, about the role of AI and machine learning in antibody engineering and targeting complex modalities, including bispecifics and ADCs. Greenside also discusses the work her organization does, what BigHat is doing to ensure the quality of data to train their AI models with, the methods of approaching harder targets such as GPCRs, and certain properties that AI can optimize better.…

1
Episode: 63 - Discussing Protein Signaling and Structural Biology With Andrew Kruse 38:18

acum 38 weeks38:18

38:18

In this episode of The Chain, host Brandon DeKosky, associate professor at MIT, speaks with Andrew Kruse, PhD, professor of biological chemistry and molecular pharmacology at Harvard University, about protein signaling and structural biology. Kruse explains what exactly bias signaling is and discusses the problems he and his team are working to resolve, as well as the tools they use to work out the dynamics of structures. He also shares the findings in signaling receptors and biology that he’s most excited about, recent advancements that have caught his attention, and the new directions for him and his lab.…

1
Episode: 62 - AI/ML in Antibody Discovery and Engineering: Reality, Hope, Future, and Hype 1:03:57

acum 43 weeks1:03:57

1:03:57

his special episode of The Chain features a panel of industry experts who discussed AI and ML in antibody discovery and engineering at this year’s PEGS Boston event. Peter Tessier, professor at the University of Michigan; Andrew Bradbury, CSO at Specifica; Andrew Waight, Senior Director of Machine Learning, Discovery Biologics & Protein Sciences at Merck Research Labs; Peyton Greenside, Co-Founder & CSO of BigHat Biosciences; and Paolo Marcatili, Director of Antibody Design at Novo Nordisk take on where AI/ML has the biggest impact, what the hype is in the use of AI/ML in antibody discovery, how new AI/ML methods are being benchmarked against traditional discovery methods, and what controls should be used in an AI/ML discovery or optimization campaign.…

1
Episode: 61 - Tomoyuki Igawa Discusses Leadership and His Experiences in Discovery and Development 55:04

acum 47 weeks55:04

55:04

In this episode of The Chain, host Tariq Ghayur, PhD, consultant and entrepreneur in residence, FairJourney Biologics, speaks with Tomoyuki Igawa, PhD, chief executive officer, Chugai Pharmabody Research in Singapore, about his 20+ years of experience in drug discovery and development. Igawa possesses a unique perspective that has allowed him and his team to develop innovative concepts, such as recycling sweeping antibodies and bispecific platforms. He discusses how the discovery and development organizations work together to provide a steady supply of products, how he builds the right team when starting a new project, and how to keep team members engaged and motivated. He also offers advice for young scientists on the importance of enjoying their work and how to maintain work-life balance.…

1
Episode: 60 - Lesley Millar-Nicholson on Technology Licensing, Navigating Patents, and Building Teams 48:14

acum 52 weeks48:14

48:14

This month The Chain shares a recent episode of the Lab Rats to Unicorns podcast. Lab Rats to Unicorns, hosted by John Flavin, aims to demystify the process of creating a great company in the life sciences, biotech, medtech, clean energy, and beyond. In this episode, Flavin speaks with Lesley Millar-Nicholson, executive director of MIT’s Technology Licensing Office (TLO). Millar-Nicholson discusses the role of the TLO, what happens after a patent is filed and licensed to a company or start-up, how she got her start in the field, and her journey from Scotland to the U.S. She also delves into finding the right people for the best team, the importance of a diverse workforce and awareness, and being around science as a non-scientist.…

1
Episode: 59 - Gabriel Rocklin on Protein Biophysics and Protein Design 33:10

acum 1 year33:10

33:10

In this month’s episode of The Chain, host Ben Hackel, professor of Chemical Engineering & Materials Science at the University of Minnesota, speaks with Gabriel Rocklin, assistant professor of Pharmacology at Northwestern University, about two recently published papers from Rocklin’s lab: one on advancing the ability to design challenging typologies and one on developing and leveraging a new technique on high-throughput protein biophysics. Rocklin shares the journey from ideation to realization of the research process, the inspiration that motivated the work, and interesting results and technological advancements discovered along the way. He also talks about the opportunities emerging from his team’s research and the challenges that still need overcoming, as well as offers advice for future scientists interested in protein biophysics.…

1
Episode: 58 - Janine Schuurman Reflects on the Key Lessons and Accomplishments of Her 20-Year Career 55:05

acum 1 year55:05

55:05

How does one maintain innovation in the antibody industry? In this episode of The Chain, host Tariq Ghayur, PhD, consultant and entrepreneur in residence, FairJourney Biologics, talks with Janine Schuurman, PhD, president of The Antibody Society, independent biotech consultant and founder of Lust for Life Sciences, about her inspiration to get into antibody engineering, her impressive career at Genmab, advice for a productive work environment, and her current work. Dr. Schuurman also shares insights on staying innovative, how to deal with the challenges of the industry, why young scientists should not be afraid to fail, as well as her plans as the new president of The Antibody Society. Links: Lust for Life Sciences: https://www.lustforlifescience.com/ The Antibody Society: https://www.antibodysociety.org/ FairJourney Biologics: https://fjbio.com/…

1
Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D. 33:06

acum 1 year33:06

33:06

Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of Bionavigen, about his thoughts on the future of bispecific ADCs, what to keep in mind when selecting targets, and how to choose the right payload. Dr. Dixit also shares his 35 years of experience with top biotech and pharmaceutical companies, including Merck, J&J, and AstraZeneca, and how he is using his expertise to advise companies with their drug development programs.…

1
Episode: 56 - Thomas Sakmar on the Golden Age for the Application of Biologics to GPCR Pharmacology 44:38

acum 1 year44:38